|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/01/19 Adaptimmune Therapeutics PLC 10-Q 6/30/19 66:6.1M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.11M
2: EX-10.1 Material Contract HTML 303K
3: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
4: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
5: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
6: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
13: R1 Document and Entity Information HTML 71K
14: R2 Unaudited Condensed Consolidated Balance Sheets HTML 97K
15: R3 Unaudited Condensed Consolidated Balance Sheets HTML 36K
(Parenthetical)
16: R4 Unaudited Condensed Consolidated Statements of HTML 60K
Operations
17: R5 Unaudited Condensed Consolidated Statements of HTML 43K
Comprehensive Loss
18: R6 Unaudited Condensed Consolidated Statements of HTML 30K
Comprehensive Loss (Parenthetical)
19: R7 Unaudited Condensed Consolidated Statement of HTML 90K
Change in Equity
20: R8 Unaudited Condensed Consolidated Statement of HTML 26K
Change in Equity (Parenthetical)
21: R9 Consolidated Statements of Cash Flows HTML 87K
22: R10 General HTML 24K
23: R11 Summary of Significant Accounting Policies HTML 46K
24: R12 Revenue HTML 54K
25: R13 Operating Leases HTML 67K
26: R14 Other expense, net HTML 45K
27: R15 Loss per share HTML 22K
28: R16 Accumulated other comprehensive income (Loss) HTML 50K
29: R17 Fair value measurements HTML 52K
30: R18 Available-for-sale debt securities HTML 71K
31: R19 Other current assets HTML 35K
32: R20 Accrued expenses and other current liabilities HTML 34K
33: R21 Share-based compensation HTML 67K
34: R22 Summary of Significant Accounting Policies HTML 50K
(Policies)
35: R23 Summary of Significant Accounting Policies HTML 65K
(Tables)
36: R24 Revenue (Tables) HTML 28K
37: R25 Operating Leases (Tables) HTML 69K
38: R26 Other expense, net (Tables) HTML 45K
39: R27 Accumulated other comprehensive income (Loss) HTML 48K
(Tables)
40: R28 Fair value measurements (Tables) HTML 50K
41: R29 Available-for-sale debt securities (Tables) HTML 67K
42: R30 Other current assets (Tables) HTML 35K
43: R31 Accrued expenses and other current liabilities HTML 34K
(Tables)
44: R32 Share-based compensation (Tables) HTML 71K
45: R33 General (Details) HTML 22K
46: R34 Summary of Significant Accounting Policies - Basis HTML 21K
of Presentation (Details)
47: R35 Summary of Significant Accounting Policies - HTML 30K
Leases - General Information (Details)
48: R36 Summary of Significant Accounting Policies - HTML 27K
Leases - Cash Flow and cost (Details)
49: R37 Summary of Significant Accounting Policies - HTML 25K
Leases - Balance Sheet Information (Details)
50: R38 Summary of Significant Accounting Policies - HTML 25K
Correction of an immaterial error (Details)
51: R39 Revenue - Revenue from contracts with customers HTML 54K
(Details)
52: R40 Operating Leases (Details)-Lease Cost HTML 34K
53: R41 Operating Leases (Details)-Maturities HTML 38K
54: R42 Other expense, net (Details) HTML 32K
55: R43 Loss per share - Antidilutive securities (Details) HTML 24K
56: R44 Accumulated other comprehensive income (Loss) HTML 24K
(Details)
57: R45 Fair value measurements (Details) HTML 38K
58: R46 Available-for-sale debt securities (Details) HTML 81K
59: R47 Other current assets (Details) HTML 36K
60: R48 Accrued expenses and other current liabilities HTML 33K
(Details)
61: R49 Share-based compensation - Share-based HTML 28K
Compensation Expense (Details)
62: R50 Share-based compensation - Options (Details) HTML 29K
64: XML IDEA XML File -- Filing Summary XML 115K
12: XML XBRL Instance -- adap-20190630x10q_htm XML 1.12M
63: EXCEL IDEA Workbook of Financial Reports XLSX 52K
8: EX-101.CAL XBRL Calculations -- adap-20190630_cal XML 148K
9: EX-101.DEF XBRL Definitions -- adap-20190630_def XML 189K
10: EX-101.LAB XBRL Labels -- adap-20190630_lab XML 744K
11: EX-101.PRE XBRL Presentations -- adap-20190630_pre XML 500K
7: EX-101.SCH XBRL Schema -- adap-20190630 XSD 110K
65: JSON XBRL Instance as JSON Data -- MetaLinks 209± 323K
66: ZIP XBRL Zipped Folder -- 0001558370-19-006758-xbrl Zip 288K
 | Download this zipped .zip folder |
| Files: | adap-20190630.xsd adap-20190630_cal.xml adap-20190630_def.xml adap-20190630_lab.xml adap-20190630_pre.xml adap-20190630ex10114cee6.htm adap-20190630ex3117d44f4.htm adap-20190630ex312d4d379.htm adap-20190630ex321083474.htm adap-20190630ex322172d5a.htm adap-20190630x10q.htm |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/06/24 Adaptimmune Therapeutics plc 10-K 12/31/23 131:16M Toppan Merrill Bridge/FA 4/18/23 Adaptimmune Therapeutics plc S-4/A 7:5.6M Toppan Merrill/FA 4/05/23 Adaptimmune Therapeutics plc S-4 7:4.5M Toppan Merrill/FA 3/06/23 Adaptimmune Therapeutics plc 10-K 12/31/22 117:15M Toppan Merrill Bridge/FA 3/14/22 Adaptimmune Therapeutics plc 10-K 12/31/21 109:13M Toppan Merrill Bridge/FA 2/25/21 Adaptimmune Therapeutics plc 10-K 12/31/20 112:13M Toppan Merrill Bridge/FA |